NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
45 hedge funds and large institutions have $31.6M invested in NeuBase Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 11 reducing their positions, and 8 closing their positions.
9% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 11
4% less funds holding
Funds holding: 47 → 45 (-2)
14% less capital invested
Capital invested by funds: $36.6M → $31.6M (-$4.99M)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
76% less call options, than puts
Call options by funds: $12K | Put options by funds: $51K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$3.36M |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$770K |
| 3 |
CM
CM Management
Gulf Breeze,
Florida
|
+$252K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$125K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$99.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.27M |
| 2 |
Renaissance Technologies
New York
|
-$902K |
| 3 |
Two Sigma Advisers
New York
|
-$466K |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$396K |
| 5 |
Two Sigma Investments
New York
|
-$310K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HF
51
HRT Financial
New York
| – | -$97K | -1,353 | Closed |
|
52
JP Morgan Chase
New York
| – | -$1K | -19 | Closed |
|
NBSE Hedge Fund Activity: Q4 2021 in Review
45 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q4 2021, worth a combined $31.6M — down 14% from $36.6M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of NBSE and 6 opened new positions — a net loss of 2 holders — while 11 trimmed existing stakes and 10 added.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $3.36M. The largest seller was GSA Capital Partners, exiting entirely with an estimated $1.27M sold.
- 45 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q4 2021, down from 47 in Q3 2021.
- Funds reported $31.6M of NeuBase Therapeutics, Inc. Common Stock stock for Q4 2021, down 14% quarter-over-quarter.
- 6 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q4 2021 and 8 closed out, a net change of -2 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q4 2021 was AIGH Capital Management, an estimated $3.36M added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q4 2021 was GSA Capital Partners, an estimated $1.27M sold.
Based on aggregated 13F filings for Q4 2021.